Abstract

Introduction: Genetic polymorphisms in TCF7L2 are the strongest common risk variants for type 2 diabetes mellitus (T2D). We and others have shown that genetic variation in TCF7L2 and WFS1 affect incretin-stimulated insulin secretion. A recent genome-wide association study discovered genetic variants associated with incretin levels. We hypothesized that these SNPs (single nucleotide polymorphisms) interact with the well-known TCF7L2 variant rs7903146 on insulin secretion due to their incretin altering effect.Methods: In this retrospective analysis, we used data from the cross-sectional TUEF-cohort (n = 2929) and a hyperglycemic clamp study using additional GLP-1 infusion at the end of the clamp (n = 76). Insulin secretion was measured by evaluating OGTT-derived indexes of insulin secretion and insulin/C-peptide levels during clamp. We genotyped rs7903146 in TCF7L2, rs10010131 in WFS1, and six SNPs associated with GLP-1 and GIP levels.Results: One of the six incretin-associated SNPs, rs17681684 in GLP2R, exhibited significant SNP x SNP interactions with rs7903146 in TCF7L2 on insulin secretion (p = 0.0024) after correction for multiple testing. Three further SNP‘s showed nominally significant interactions (p < 0.05). In the hyperglycemic clamp study, rs7903146 in TCF7L2 also interacted with rs17681684 on AUC C-peptide during the GLP-1 stimulation phase, thereby replicating the above finding.Conclusion: The findings exemplify the role of SNP x SNP interactions in the genetics of type 2 diabetes mellitus and corroborate the existence of clinically relevant differences in incretin sensitivity.

Highlights

  • Genetic polymorphisms in transcription factor 7-like 2 (TCF7L2) are the strongest common risk variants for type 2 diabetes mellitus (T2D)

  • Using hyperglycemic clamps with glucagon-like peptide-1 (GLP-1) infusion [6], we have previously shown that this TCF7L2-implicated defect in insulin secretion involves insulin secretion stimulated by incretin action [7, 8]

  • Another diabetes-related variant in the locus WFS1 was shown to comparably impact incretin-sensitivity of the beta cell [2, 9]. Incretins such as gastric inhibitory peptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagonlike peptide-2 (GLP-2) are peptide hormones released from the small intestine [10,11,12]

Read more

Summary

Introduction

Genetic polymorphisms in TCF7L2 are the strongest common risk variants for type 2 diabetes mellitus (T2D). A recent genome-wide association study discovered genetic variants associated with incretin levels We hypothesized that these SNPs (single nucleotide polymorphisms) interact with the well-known TCF7L2 variant rs7903146 on insulin secretion due to their incretin altering effect. Carriers of the TCF7L2 risk allele have a significantly increased risk to develop type 2 diabetes mellitus [4] This is due to impaired insulin secretion associated with the risk variant. Using hyperglycemic clamps with GLP-1 infusion [6], we have previously shown that this TCF7L2-implicated defect in insulin secretion involves insulin secretion stimulated by incretin action [7, 8] Another diabetes-related variant in the locus WFS1 was shown to comparably impact incretin-sensitivity of the beta cell [2, 9]. GLP-1 and GIP are key factors of diet induced stimulation of insulin secretion accounting for up to 70% of postprandial insulin secretion [13]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call